BÜHLMANN Laboratories AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- -
- Established
- 1976-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.buhlmannlabs.ch/
BÜHLMANN FPELA in the Diagnosis of Exocrine Pancreatic Insufficiency
Completed
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- Diagnostic Test: BÜHLMANN fPELA assay
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bühlmann Laboratories AG
- Target Recruit Count
- 201
- Registration Number
- NCT04548778
- Locations
- 🇩🇪
Universitätsklinikum Halle (Saale), Halle (Saale), Germany
IBDoc® Canadian User Performance Evaluation
Not Applicable
Completed
- Conditions
- Inflammatory Bowel Diseases
- Interventions
- Diagnostic Test: IBDoc calprotectin testOther: questionnaire
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- Bühlmann Laboratories AG
- Target Recruit Count
- 61
- Registration Number
- NCT03408249
- Locations
- 🇨🇦
GIRI (GI Research Institute), Vancouver, British Columbia, Canada
🇨🇦Hôtel-Dieu de Lévis,, Lévis, Quebec, Canada
🇨🇦Division of Gastroenterology, Department of Medicine, Faculty of Medicine University of Alberta,, Edmonton, Alberta, Canada
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Completed
- Conditions
- Irritable Bowel SyndromeInflammatory Bowel Disease
- Interventions
- Other: fecal calprotectin level
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2019-01-18
- Lead Sponsor
- Bühlmann Laboratories AG
- Target Recruit Count
- 478
- Registration Number
- NCT02351635
- Locations
- 🇺🇸
Beth israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Gastro Health, Miami, Florida, United States
🇺🇸Stanford Center for Clinical & Translational Research & Education, Palo Alto, California, United States
© Copyright 2025. All Rights Reserved by MedPath